Importantly, in line with the fact that a highly immature phenotype is associated with more aggressive disease, we unveiled that all favorable-risk AML patients showed an increase in the expression of almost all markers (including CD2, CD8, CD49e, and CD146) in comparison to intermediate- or adverse-risk AML patients. The gene discussed is CD8A; the disease is acute myeloid leukemia.